Press Releases

Year

October 1, 2020

JAMA Ophthalmology Publishes Pooled Analysis of Data from two Phase 3 Clinical Trials of Upneeq™ (oxymetazoline hydrochloride, 0.1% solution) for Acquired Ptosis

-- Phase 3 trials showed UPNEEQ was associated with positive outcomes after instillation on days 1 and 14 and was well-tolerated, demonstrating its potential promise for the treatment of acquired ptosis -- BRIDGEWATER, N.J. , Oct. 01, 2020 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, Inc.

September 2, 2020

Osmotica to Present at 2020 Wells Fargo Virtual Healthcare Conference

BRIDGEWATER, N.J. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison , Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present

August 11, 2020

Osmotica Pharmaceuticals plc Reports Second Quarter 2020 Results and Provides Business Updates

Second quarter 2020 total revenue of $37.5 million Received U.S Food and Drug Administration (“FDA”) approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for acquired blepharoptosis (ptosis or droopy eyelid) in adults Entered into exclusive license agreement with Santen

August 6, 2020

Osmotica Pharmaceuticals plc to Provide Second Quarter 2020 Business and Financial Update and Presentation on Upneeq™ on August 11, 2020

-Company to discuss launch plans for Upneeq and will be joined by Dr. Derek Cunningham, OD, FAAO- BRIDGEWATER, N.J. , Aug. 06, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the

July 28, 2020

Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, Enter into an Exclusive License Agreement in Japan, Asia, and EMEA for RVL-1201, a First-in-Class Treatment for Acquired Blepharoptosis

OSAKA, Japan and BRIDGEWATER, N.J. , July 28, 2020 (GLOBE NEWSWIRE) -- Santen Pharmaceutical Co., Ltd (hereinafter, Santen) and RVL Pharmaceuticals, Inc. , a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (hereinafter, Osmotica), announced today an exclusive license agreement covering

July 20, 2020

Osmotica Pharmaceutical US LLC Announces FDA User Fee Goal Date of December 29, 2020 for Arbaclofen Extended Release Tablets

BRIDGEWATER, N.J. , July 20, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) through its subsidiary Osmotica Pharmaceutical US LLC (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that the U.S.

July 13, 2020

Osmotica Announces Pricing of Public Offering of Ordinary Shares

BRIDGEWATER, N.J. , July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the pricing of its previously announced public offering of 5,000,000 ordinary shares at a price to the

July 13, 2020

Osmotica Announces Proposed Public Offering of Ordinary Shares

BRIDGEWATER, N.J. , July 13, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today the commencement of a proposed public offering of 5,000,000 ordinary shares.

July 9, 2020

Osmotica Pharmaceuticals plc Receives FDA Approval for Upneeq™ (oxymetazoline hydrochloride ophthalmic solution), 0.1% for Acquired Blepharoptosis (Droopy Eyelid) in Adults

-- First and only FDA-approved pharmacologic treatment for acquired blepharoptosis -- -- Company to host Investor Call at 10:00 a.m. ET today to discuss approval, key elements of the clinical data and commercial plans -- BRIDGEWATER, N.J , July 09, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals

June 30, 2020

Osmotica Pharmaceuticals US LLC Submits Amended NDA for Arbaclofen Extended Release Tablets to U.S. Food and Drug Administration

-- Submission based on world’s largest database of patients treated for spasticity associated with Multiple Sclerosis -- -- Demonstrated efficacy, tolerability and one-year safety results on 80 mg/day -- BRIDGEWATER, N.J. , June 30, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq:

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 22

Investor Relations

News

Press Releases

Press Releases

Press Releases